Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced an update to its full year 2021 revenue guidance originally provided on March 31, 2021.
"We saw increased and sustained clinical volume activity during the first quarter, which, coupled with our improved reimbursement rates translated into higher revenues overall for Interpace than initially forecasted,” said Thomas W. Burnell, CEO and President. “We now expect 2021full year revenue to be in the range of $42 to $44 million as compared to our prior guidance of $38 to $40 million provided at the time of our full year and fourth quarter 2020 earning’s announcement. This represents an approximate 30% to 36% improvement over our 2020 full year revenue.” Burnell added, “With the revenue growth and restructuring progressing as planned, expectations remain to achieve our goal of EBITDA break-even by the end of 2021. We will provide additional detail when we report the Company’s first quarter results in May.”
https://finance.yahoo.com/news/interpace-biosciences-raises-full-2021-110500873.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.